Overview
My research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution. On the clinical side we are currently conducting approximately 50 different clinical protocols ranging from preparatory regimens, supportive care studies and disease specific protocols. Most of these clinical studies are centered around studies of the sources of stem cells and the methods to improve the long term outcome. There are exploratory protocols for novel therapies such as dendritic cell therapy for several malignancies, antiangiogenesis therapy, graft engineering to prevent graft-versus-host disease and antigen specific T cells or non specific NK cells to prevent relapse. Moreover a strong focus of the program is to develop cord-blood transplantation for adult patients with hematologic malignancies. The laboratory studies center on understanding the immunological events that occur with graft-vs-host disease and methods to prevent this disease. The current efforts focus on understanding murine reconstitution following transplantation, use of a peptide polymer to block MHC class II recognition of minor histocompatibility antigens, use of T cell engineering to prevent graft-versus-host disease at the same time preserving a graft-versus-malignancy effect.
For more information see http://ed-media.mc.duke.edu/BMT.nsf
For more information see http://ed-media.mc.duke.edu/BMT.nsf
Current Duke Appointments & Affiliations
Donald D. and Elizabeth G. Cooke Cancer Distinguished Research Professor
·
2002 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Professor of Medicine
·
2001 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Professor in Integrative Immunobiology
·
2001 - Present
Integrative Immunobiology,
Basic Science Departments
Professor in Pathology
·
2011 - Present
Pathology,
Clinical Science Departments
Research Professor of Global Health
·
2018 - Present
Duke Global Health Institute,
University Institutes and Centers
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Chief, Division of Cell Therapy in the Department of Medicine
·
2004 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Scholarly Works
New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT.
Journal article Blood · October 2, 2026 The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia ... Full text Link to item CiteYou Are Already Trained for This: The Hematologist/Oncologist's Role in Radiation Mass Casualty Response.
Journal article Blood · September 25, 2026 A large-scale radiation injury or nuclear incident requires an immediate, coordinated medical response that vastly exceeds traditional disaster management frameworks. While specialized networks exist, the initial surge of casualties will inevitably place a ... Full text Link to item CiteEarly Mortality and Conditional Long-Term Survival After Adult Umbilical Cord Blood Transplantation: A 1-Year Landmark Analysis.
Journal article Transplant Cell Ther · August 15, 2026 Umbilical cord blood (UCB) is an established alternative graft source for allogeneic hematopoietic cell transplantation (HCT), but adult use is limited by substantial early morbidity and mortality. Conventional survival estimates from transplantation may o ... Full text Link to item CiteRecent Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Center for Advancing Translational Sciences · 2025 - 2030The Gut Microbiome and Development of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Children
ResearchCo-Mentor · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2030Stimulating Access to Research in Residency (StARR) - NIAID
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of Allergy and Infectious Diseases · 2018 - 2029View All Grants
Education
Yale University ·
1981
M.D.